A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to
evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment
of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5)
deficiency disorder (CDD).